|
|
Article: Schering-Plough and Texas Biotechnology Form Alliance to Discover, Develop VLA-4 Antagonist Drugs to Treat Asthma.
- Article from:
- PR Newswire
- Article date:
- July 10, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MADISON, N.J. and HOUSTON, July 10 /PRNewswire/ --
Schering-Plough Corporation (NYSE: SGP) and Texas Biotechnology Corporation (Amex: TBC) today announced a worldwide research collaboration and license agreement to discover, develop and commercialize VLA-4 antagonists. VLA-4 antagonists represent a new class of compounds that has shown promise in multiple preclinical animal models of asthma. The primary focus of the collaboration will be to discover orally available VLA-4 antagonists as treatments for asthma.
Richard Dixon, Ph.D., chief scientific officer and senior vice president of research, Texas Biotechnology, stated, "We believe the mechanism of ...